Tyra Biosciences
TYRA
46 hedge funds and large institutions have $268M invested in Tyra Biosciences in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 4 closing their positions.
363% more call options, than puts
Call options by funds: $37K | Put options by funds: $8K
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.16% less ownership
Funds ownership: 86.67% → 83.51% (-3.2%)
6% less funds holding
Funds holding: 49 → 46 (-3)
16% less capital invested
Capital invested by funds: $320M → $268M (-$51.9M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$7.38M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$410K |
| 3 |
BlackRock
New York
|
+$233K |
| 4 |
JAFL
Jay A. Fishman Ltd
Troy,
Michigan
|
+$81.3K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$50.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$12M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.54M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.04M |
| 4 |
JP Morgan Chase
New York
|
-$144K |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$116K |
TYRA Hedge Fund Activity: Q4 2022 in Review
46 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q4 2022, worth a combined $268M — down 16% from $320M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TYRA and 1 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 17 added.
The largest buyer was TCG Crossover Management, adding an estimated $7.38M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $12M sold.
- 46 institutional investors held Tyra Biosciences (TYRA) as of Q4 2022, down from 49 in Q3 2022.
- Funds reported $268M of Tyra Biosciences stock for Q4 2022, down 16% quarter-over-quarter.
- 1 fund opened new Tyra Biosciences positions in Q4 2022 and 4 closed out, a net change of -3 holders.
- The largest Tyra Biosciences buyer in Q4 2022 was TCG Crossover Management, an estimated $7.38M added.
- The largest Tyra Biosciences seller in Q4 2022 was Janus Henderson Group, an estimated $12M sold.
Based on aggregated 13F filings for Q4 2022.